gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · SRZNHealthcareBiotechnology

Surrozen, Inc. Common (SRZN)

$31.65+5.08%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$31.65▲ 151.39% in range
Nov 4, 2025Low $11.80 · High $34.13Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Surrozen, Inc. Common closed at $31.65 on Nov 4, up 5.08%, 7.3% below its 52-week closing high. Volume of 231.1K shares was 0.47× its 20-day average (below normal).

Split-adjusted performance: +20.0% over one month, -7.3% over six months, +142.3% over one year.

In the quarter ended Jun 30, 2026, revenue was $5M, up 408.6% from a year earlier, with a net margin of 640.8%.

Short interest was 3.1M shares at the Oct 15 settlement, up 43.0% from the prior report (37.0% of float, 4.8 days to cover).

Market cap$372.0M11.8M shares
Revenue · quarter$5.0M+408.6% YoY
Diluted EPS$-0.41−116.1% YoY
P/E · TTM—P/S 32.3×
Net margin640.8%Gross 100.0%
Dividend yieldNone
52-week range11.80 – 34.13−7.3% from high
Volume231.1K0.47× 20-day avg
Volatility · 60d171.0%Annualised
Short % of float37.0%4.8 days to cover
Net cash$102.0MCash $102.0M
Next earnings—Not scheduled
Split-adjusted performance
1W +4.3%1M +20.0%3M +46.3%6M −7.3%YTD +40.0%1Y +142.3%3Y +455.3%5Y −67.2%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum61
Revenue growth93
Net margin99
Value (low P/E)—
Size59

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short3.1M+43.0% vs prior
Days to cover4.8Settled Oct 15
% of float37.0%
Short vol. 10d58.5%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
SRZNSurrozen$31.65+5.08%−7.3%+408.6%640.8%—$372.0M
FENCFennec Pharmaceuticals$10.35−3.27%+44.2%+85.2%11.0%—$362.9MCompare
CCCCC4 Therapeutics$3.12−2.80%+6.5%+2.8%−355.9%—$383.8MCompare
ZURAZura Bio Limited$4.02+0.75%−17.8%———$387.2MCompare
TECXTectonic Therapeutic$20.30+6.95%−30.0%———$396.9MCompare
EIKNEikon Therapeutics$6.39+15.14%−35.9%———$346.1MCompare
ALLOAllogene Therapeutics$1.19+6.25%−48.5%—−919.8%—$411.1MCompare
EDITEditas Medicine$2.72+4.62%−14.3%+232.3%−153.3%—$417.7MCompare
XFORX4 Pharmaceuticals$3.24+2.21%−26.0%+346.3%−183.5%—$321.2MCompare

News about Surrozen

All news →

No recent articles focused on Surrozen. 1 articles mention it in passing.

Quick answers

What does Surrozen, Inc. Common do?
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).
What is SRZN's market cap?
$372M, based on the Nov 4 close of $31.65.
Does Surrozen, Inc. Common pay a dividend?
No regular cash dividend has been paid in the last year.
How much of SRZN is sold short?
3.1M shares, 37.0% of float, as of Oct 15, 2026.
What sector is SRZN in?
Healthcare, in the Biotechnology industry.

About Surrozen

Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).

HQ: South San Francisco, CA44 employeesListed Aug 12, 2021surrozen.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology